27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
These results, together with previous studies, suggest that memantine represents a new approach for the treatment of patients with moderate to severe AD. 3 key findings →
Participants: 203 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In the estrogen-alone trial, 47 participants were diagnosed with probable dementia, of whom 28 were assigned to CEE and 19 to placebo (hazard ratio [HR], 1.49; 95% confidence interval [CI], 0.83-2.66). 3 key findings →
Participants: 4,532 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
For women aged 65 years or older, hormone therapy had an adverse effect on cognition, which was greater among women with lower cognitive function at initiation of treatment. 1 key finding →
Participants: 1,387 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This double-blind randomized trial does not support the hypothesis that the use of soy protein supplement containing isoflavones improves cognitive function, bone mineral density, or plasma lipids in healthy postmenopausal women when started at the age of 60 years or later. 2 key findings →
Design: randomized controlled trial Participants: 175 Evidence: high
Full summary, score breakdown and related studies → Original source
The outcomes were better among patients treated with rivastigmine than among those who received placebo; however, the differences between these two groups were moderate and similar to those reported in trials of rivastigmine for Alzheimer's disease. 3 key findings →
Participants: 541 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Fewer than half of the older adults dispensed donepezil in Ontario would have been eligible to participate in the RCTs that established the efficacy of this drug. 4 key findings →
Design: systematic review Participants: 3,423 Evidence: high
Full summary, score breakdown and related studies → Original source
A total of 267 (3.8%) women had diabetes and 297 (4.2%) had IFG. 3 key findings →
Design: randomized controlled trial Participants: 267 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Donepezil has significant efficacy in the treatment of neuropsychiatric symptoms in patients with mild to moderate AD. 4 key findings →
Design: open-label trial Participants: 134 Evidence: high
Full summary, score breakdown and related studies → Original source
Although significant treatment effects were not seen in the primary efficacy measures, outcomes on secondary measures suggest promising directions for further evaluation of donepezil treatment in patients with MCI. 2 key findings →
Participants: 133 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Of 275 patients, 51 (18.5%) had persistent coma and died in the hospital. 2 key findings →
Design: cohort study Participants: 275 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A long-term CMI in ChEI-treated early Alzheimer disease patients produced additional mood and cognitive benefits. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Exercise training increases fitness, physical function, cognitive function, and positive behavior in people with dementia and related cognitive impairments. 3 key findings →
Design: meta-analysis Participants: 2,020 Evidence: high
Full summary, score breakdown and related studies → Original source
Hippocampal volume is reduced in patients with unipolar depression, maybe as a consequence of repeated periods of major depressive disorder. 2 key findings →
Design: systematic review Participants: 351 Evidence: high
Full summary, score breakdown and related studies → Original source
A risk score based on 12 variables from the MDS estimates 6-month mortality for nursing home residents with advanced dementia with greater accuracy than existing prognostic guidelines. 5 key findings →
Design: cohort study Participants: 6,799 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this population, among those who progressed to dementia, 60% progressed to AD and 33% to VaD. 2 key findings →
Design: longitudinal study Participants: 2,963 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The failure of selective cyclo-oxygenase-2 inhibition to slow the progression of AD may indicate either that the disease process is too advanced to modify in patients with established dementia or that cyclo-oxygenase-2 does not play a significant role in the pathogenesis of the disorder. 5 key findings →
Participants: 692 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cognition averaged 0.8 MMSE (mini-mental state examination) points better (95% CI 0.5-1.2; p<0.0001) and functionality 1.0 BADLS points better (0.5-1.6; p<0.0001) with donepezil over the first 2 years. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Incident use of neuroleptics in Ontario nursing homes is substantial. 3 key findings →
Design: cohort study Participants: 19,780 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The techniques evaluated were person-centered showering and the towel bath (a person-centered, in-bed bag-bath with no-rinse soap). 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Hospice enrollment correlates with reduced Medicare expenditures among younger decedents with cancer but increased expenditures among decedents without cancer and those older than 84 years of age. 2 key findings →
Design: retrospective cohort Participants: 245 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cognitive decline over 36 months of continuous galantamine treatment was substantially less than the predicted cognitive decline of untreated patients with mild to moderate dementia. 5 key findings →
Design: open-label trial Participants: 119 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This cost-consequence analysis reveals economic benefits of treatment of moderate to severe AD with donepezil. 1 key finding →
Participants: 144 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The measured benefits in clinical trials for the treatment of mixed dementia are best described as statistically significant differences in cognitive test scores and clinician and caregiver impressions of change. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Persons dying with advanced dementia admitted to nursing homes have different characteristics compared to those admitted to home care services. 3 key findings →
Design: cohort study Participants: 2,730 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Medical record documentation reflects physician recognition of dementia, yet physicians are aware of, but have not documented, many patients with milder cognitive impairment. 2 key findings →
Design: cohort study Participants: 365 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →